Improve analytics capabilities
Challenge Market Analytics leaders in a global Big Pharma’s European affiliates were concerned that their preparing of a high number of forecast scenarios was not helping decision making To address this they wanted to assess probabilistic forecasting as an approach to improve decision-making efficiency Solution Created and ran a one-day workshop with Analytics teams from […]
Create insight for R&D partnerships
Challenge A biotech with a specific therapeutic expertise had developed two lead assets that had potential in several non-core indications and sought partnerships to progress its assets Business Development activities had stalled and had not yielded sufficient contact with the senior R&D executives who would be open to creative partnership approaches for the various indications […]
Align and engage medical affairs
Challenge A Big Pharma Medical Affairs team for a leading immunotherapy portfolio was not delivering as effectively as it could across the multiple indications it was covering The organisational structure and operating model did not support the complexity of multi-indication medical information requirements Solution Interviewed all Medical Affairs and related stakeholders to understand the constraints […]
Develop insight and focus to raise funds
Challenge An early stage biotech sought competitive insight and a business development narrative to support fund-raising and the consideration of suitable partnership deals to enable expansion The biotech’s technology was highly innovative with a corresponding recent rapid growth in the number of companies and pipeline products that were either precedents or competitors Solution We carried […]
Create corporate growth strategy
Challenge An early-stage biotech with a highly innovative new technology that had multiple therapeutic area and indication possibilities sought a focus for its further product and technology developments The management team and board did not have an evidence-based view on which opportunities were the best ones to pursue for further corporate growth Solution Analysed and […]
Optimise commercial strategy
Challenge A multi-product biotech with a newly established commercial footprint in the US was not getting the speed of uptake that was expected prior to launch The specialty product was not straightforward to commercialise as it required a procedure, an associated device and a relationship approach with key centres spread across the US Solution Analysed […]
Improve discovery portfolio decision-making
Challenge The available resource, budget and value data was more suited to clinical projects, and the leadership team did not have a synthetic and succinct dashboard to track discovery activities Solution Established the principles, goals and scope of information that the discovery leaders needed to make better decisions Clarified the sources of relevant information, the […]
Accelerate access to excellent partners
Challenge A biotech with on-market assets and a novel technology platform needed partners across different regions as it could not fully self-fund global development and commercialisation The biotech did not have a rich understanding and network into one of its key target regions for partnerships, and needed to accelerate its senior-level access in the right […]
Create a clear external growth plan
Challenge Following a period of profitability constraints, a MidPharma was poised for adding external partnerships and bolt-on acquisitions and needed a prioritised set of candidates to approach with a strong rationale for each The management team had differing views on the relative attractiveness of different candidates and how they would fit the corporate strategy Solution […]
Plan more focused external innovation
Challenge Ambitious targets for pipeline growth in a MidPharma led to a request for R&D to establish how it could do more external innovation in order to support achievement of the new goals The external innovation team was under-resourced and traditionally focused on earlier technology collaborations rather than the pipeline enrichment that was newly required […]